Study of Metastatic Ocular Melanoma

Melanoma Inhibitory Activity (MIA): A Serological Marker for Metastatic Uveal Melanoma

NCT00406900 ·Status: UNKNOWN

Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by Surgery

NCT01835145 ·Status: COMPLETED ·Phase: PHASE2

Triple BRAFinh/MEKinh /antiPD1 Combined Therapy in Patients With BRAF Mutated Melanoma With Central Nervous System Metastasis

NCT05510466 ·Status: UNKNOWN

Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma

NCT05789043 ·Status: RECRUITING ·Phase: PHASE3

Study of First-line Treatment Patterns and Clinical Outcomes in Patients With Advanced Melanoma in the United Kingdom

NCT03448497 ·Status: COMPLETED

Temozolomide or Selumetinib in Treating Patients With Metastatic Melanoma of the Eye

NCT01143402 ·Status: COMPLETED ·Phase: PHASE2

Molecularly Targeted Therapy in Treating Patients With BRAF Wild-type Melanoma That is Metastatic

NCT02094872 ·Status: COMPLETED ·Phase: PHASE2

Precision Radiation of Immune Checkpoint Therapy Resistant Melanoma Metastases

NCT04793737 ·Status: RECRUITING ·Phase: NA

Biomarkers for the Activity of Immune Checkpoint Inhibitor Therapy in Patients With Advanced Melanoma

NCT02673970 ·Status: RECRUITING

Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma

NCT01709162 ·Status: TERMINATED ·Phase: PHASE2

O6-benzylguanine and Carmustine in Treating Patients With Unresectable Locally Recurrent or Metastatic Melanoma

NCT00005961 ·Status: COMPLETED ·Phase: PHASE2

A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma

NCT03153085 ·Status: COMPLETED ·Phase: PHASE2

Carboplatin and Temozolomide in Treating Patients With Unresectable or Metastatic Melanoma

NCT00003747 ·Status: UNKNOWN ·Phase: PHASE1

Open-Label Study of TPI 287 for Patients With Metastatic Melanoma

NCT01340729 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

Phase 1 Study of MPC-6827 and Temozolomide in Metastatic Melanoma

NCT00609011 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma

NCT06008106 ·Status: RECRUITING ·Phase: PHASE3

Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma

NCT02535078 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2

Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma

NCT01376713 ·Status: COMPLETED ·Phase: PHASE2

A Combination of Ipilimumab and Fotemustine for Treat Unresectable Locally Advanced or Metastatic Melanoma

NCT01654692 ·Status: COMPLETED ·Phase: PHASE2

Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma

NCT01703507 ·Status: COMPLETED ·Phase: PHASE1

Comparative Microarray Analysis in Primary Cutaneous Malignant Melanoma

NCT01482260 ·Status: COMPLETED

Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma

NCT02388906 ·Status: COMPLETED ·Phase: PHASE3

Topotecan and Melphalan for Retinoblastoma

NCT04799002 ·Status: RECRUITING ·Phase: PHASE3

Melphalan Chemoreduction for Ocular Melanoma

NCT05893654 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1/PHASE2

Circulating Melanoma Cells in Metastatic Patients Treated With Selective BRAF Inhibitors

NCT01878396 ·Status: UNKNOWN